NeOnc Technologies Receives UAE IND Approval for NEO212 in Brain Cancer

On June 16, 2026, NeOnc Technologies Holdings, Inc. announced that the Department of Health – Abu Dhabi (DOH) granted Investigational New Drug (IND) status for NEO212, an orally administered perillyl alcohol-temozolomide carbamate conjugate. This marks the first international regulatory clearance for NEO212, which is being developed for aggressive brain tumors, including glioblastoma and brain metastases. The approval follows the completion of a Phase 1 dose-escalation study that established 610 mg as the recommended Phase 2 dose and showed early signs of clinical activity and disease stabilization. NeOnc plans to advance NEO212 into Phase 2 clinical development in the UAE while continuing discussions with the U.S. FDA regarding a potential registrational pathway. Additionally, the company has submitted IND applications to the DOH for its NEO100 clinical programs (NEO100-01, -02, and -03) and is currently awaiting regulatory decisions. Enrollment in the UAE for NEO212 is pending final Institutional Review Board approval and protocol amendments.